Playing the long game: will the ongoing evolution of the psoriasis market play out in atopic dermatitis?

With several advanced therapy options now available to treat moderate-severe atopic dermatitis - and more on the horizon - how is the treatment landscape changing? Can we use evolutions in psoriasis treatment as a proxy, and can we draw any parallels between physicians’ therapeutic goals?

Ipsos | Playing the long game In a follow-up edition to our 2019 point of view The Biologic Blueprint, we use Ipsos’ syndicated Atopic Dermatitis and Psoriasis Therapy Monitor data to compare developments across the two indications now additional advanced therapy options are available, and how physicians’ treatment goals and expectations are evolving in tandem.

Download the white paper

The author(s)

More insights about Health

Related news

  • The Human Advantage Conference 2026: Highlights

    The Human Advantage Conference 2026: Highlights

    Ipsos is proud to support The Human Advantage 2026, a flagship event bringing together some of the world's leading experts and key industry figures to explore how behavioural science, AI, and human intelligence can address the critical challenges facing businesses and society. Here's a look back at two days of live coverage.
  • [WEBINAR] KEYS: Dialling Up the S In Sustainability
    KEYS Events replay

    [REPLAY] KEYS: Dialling Up the S In Sustainability

    In the next episode of our KEYS webinar, we’ll be asking whether now is the time when organisations should be ‘dialling up the S’ in their sustainability initiatives.
  • [Webinar] Real-World Evidence: Empowering the Patient
    Healthcare Webinar

    [Replay] Real-World Evidence: Empowering the Patient

    Patient voices are now central to regulatory, HTA and commercial decisions. But how do we move beyond tick-box engagement to evidence that truly reflects lived experience? Join our expert panel for a 360° perspective on making patient-centricity work in practice.